keyword
MENU ▼
Read by QxMD icon Read
search

memantine randomised controlled trial

keyword
https://www.readbyqxmd.com/read/27739182/cost-effectiveness-of-donepezil-and-memantine-in-moderate-to-severe-alzheimer-s-disease-the-domino-ad-trial
#1
Martin Knapp, Derek King, Renée Romeo, Jessica Adams, Ashley Baldwin, Clive Ballard, Sube Banerjee, Robert Barber, Peter Bentham, Richard G Brown, Alistair Burns, Tom Dening, David Findlay, Clive Holmes, Tony Johnson, Robert Jones, Cornelius Katona, James Lindesay, Ajay Macharouthu, Ian McKeith, Rupert McShane, John T O'Brien, Patrick P J Phillips, Bart Sheehan, Robert Howard
OBJECTIVE: Most investigations of pharmacotherapy for treating Alzheimer's disease focus on patients with mild-to-moderate symptoms, with little evidence to guide clinical decisions when symptoms become severe. We examined whether continuing donepezil, or commencing memantine, is cost-effective for community-dwelling, moderate-to-severe Alzheimer's disease patients. METHODS: Cost-effectiveness analysis was based on a 52-week, multicentre, double-blind, placebo-controlled, factorial clinical trial...
October 13, 2016: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/27737513/pharmacologic-interventions-for-treating-phantom-limb-pain
#2
REVIEW
Maria Jenelyn M Alviar, Tom Hale, Monalisa Dungca
BACKGROUND: This is an updated version of the original Cochrane review published in Issue 12, 2011. Phantom limb pain (PLP) is pain that arises in the missing limb after amputation and can be severe, intractable, and disabling. Various medications have been studied in the treatment of phantom pain. There is currently uncertainty in the optimal pharmacologic management of PLP. OBJECTIVES: This review aimed to summarise the evidence of effectiveness of pharmacologic interventions in treating PLP...
October 14, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27393698/withdrawal-of-antidementia-drugs-in-older-people-who-when-and-how
#3
Carole Parsons
The evidence base to guide withdrawal of antidementia medications in older people with dementia is limited; while some randomised controlled studies have considered discontinuation of cholinesterase inhibitors (ChEIs), no such studies examining discontinuation of the N-methyl-D-aspartate receptor antagonist memantine have been conducted to date. The purpose of this opinion article was to summarise the existing evidence on withdrawal of cholinesterase inhibitors and memantine, to highlight the key considerations for clinicians when making these prescribing decisions and to offer guidance as to when and how treatment might be discontinued...
August 2016: Drugs & Aging
https://www.readbyqxmd.com/read/27121704/interventions-to-delay-functional-decline-in-people-with-dementia-a-systematic-review-of-systematic-reviews
#4
Kate Laver, Suzanne Dyer, Craig Whitehead, Lindy Clemson, Maria Crotty
OBJECTIVE: To summarise existing systematic reviews that assess the effects of non-pharmacological, pharmacological and alternative therapies on activities of daily living (ADL) function in people with dementia. DESIGN: Overview of systematic reviews. METHODS: A systematic search in the Cochrane Database of Systematic Reviews, DARE, Medline, EMBASE and PsycInfo in April 2015. Systematic reviews of randomised controlled trials conducted in people with Alzheimer's disease or dementia measuring the impact on ADL function were included...
2016: BMJ Open
https://www.readbyqxmd.com/read/26983548/glutamatergic-medication-in-the-treatment-of-obsessive-compulsive-disorder-ocd-and-autism-spectrum-disorder-asd-study-protocol-for-a-randomised-controlled-trial
#5
Alexander Häge, Tobias Banaschewski, Jan K Buitelaar, Rick M Dijkhuizen, Barbara Franke, David J Lythgoe, Konstantin Mechler, Steven C R Williams, Ralf W Dittmann
BACKGROUND: Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders that emerge in childhood or adolescence. Despite the effectiveness of serotonergic compounds in the treatment of obsessive-compulsive disorder, treatment-resistant symptoms remaining in 40 to 60 % of patients present a pressing clinical problem. There are currently no medications that effectively treat the core impairments of autism spectrum disorder. There is an urgent need for the development of conceptually novel pharmacological strategies...
2016: Trials
https://www.readbyqxmd.com/read/26515660/nursing-home-placement-in-the-donepezil-and-memantine-in-moderate-to-severe-alzheimer-s-disease-domino-ad-trial-secondary-and-post-hoc-analyses
#6
RANDOMIZED CONTROLLED TRIAL
Robert Howard, Rupert McShane, James Lindesay, Craig Ritchie, Ashley Baldwin, Robert Barber, Alistair Burns, Tom Dening, David Findlay, Clive Holmes, Robert Jones, Roy Jones, Ian McKeith, Ajay Macharouthu, John O'Brien, Bart Sheehan, Edmund Juszczak, Cornelius Katona, Robert Hills, Martin Knapp, Clive Ballard, Richard G Brown, Sube Banerjee, Jessica Adams, Tony Johnson, Peter Bentham, Patrick P J Phillips
BACKGROUND: Findings from observational studies have suggested a delay in nursing home placement with dementia drug treatment, but findings from a previous randomised trial of patients with mild-to-moderate Alzheimer's disease showed no effect. We investigated the effects of continuation or discontinuation of donepezil and starting of memantine on subsequent nursing home placement in patients with moderate-to-severe Alzheimer's disease. METHODS: In the randomised, double-blind, placebo-controlled Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial, community-living patients with moderate-to-severe Alzheimer's disease (who had been prescribed donepezil continuously for at least 3 months at a dose of 10 mg for at least the previous 6 weeks and had a score of between 5 and 13 on the Standardised Mini-Mental State Examination) were recruited from 15 secondary care memory centres in England and Scotland and randomly allocated to continue donepezil 10 mg per day without memantine, discontinue donepezil without memantine, discontinue donepezil and start memantine 20 mg per day, or continue donepezil 10 mg per day and start memantine 20 mg per day, for 52 weeks...
December 2015: Lancet Neurology
https://www.readbyqxmd.com/read/26513128/pharmacological-interventions-for-cognitive-decline-in-people-with-down-syndrome
#7
REVIEW
Nuala Livingstone, Jennifer Hanratty, Rupert McShane, Geraldine Macdonald
BACKGROUND: People with Down syndrome are vulnerable to developing dementia at an earlier age than the general population. Alzheimer's disease and cognitive decline in people with Down syndrome can place a significant burden on both the person with Down syndrome and their family and carers. Various pharmacological interventions, including donepezil, galantamine, memantine and rivastigmine, appear to have some effect in treating cognitive decline in people without Down syndrome, but their effectiveness for those with Down syndrome remains unclear...
2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26447539/interventions-for-fatigue-in-parkinson-s-disease
#8
REVIEW
Roy G Elbers, John Verhoef, Erwin Eh van Wegen, Henk W Berendse, Gert Kwakkel
BACKGROUND: Factors contributing to subjective fatigue in people with idiopathic Parkinson's disease (PD) are not well known. This makes it difficult to manage fatigue effectively in PD. OBJECTIVES: To evaluate the effects of pharmacological and non-pharmacological interventions, compared to an inactive control intervention, on subjective fatigue in people with PD. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); MEDLINE (via PubMed); Ovid EMBASE; EBSCO CINAHL; Ovid PsycINFO; PEDro; and the WHO International Clinical Trials Registry Platform Search Portal up to April 2015...
2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26415966/ketamine-and-other-glutamate-receptor-modulators-for-depression-in-bipolar-disorder-in-adults
#9
REVIEW
Tayla L McCloud, Caroline Caddy, Janina Jochim, Jennifer M Rendell, Peter R Diamond, Claire Shuttleworth, Daniel Brett, Ben H Amit, Rupert McShane, Layla Hamadi, Keith Hawton, Andrea Cipriani
BACKGROUND: There is emerging evidence that glutamatergic system dysfunction might play an important role in the pathophysiology of bipolar depression. This review focuses on the use of glutamate receptor modulators for depression in bipolar disorder. OBJECTIVES: 1. To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder.2. To review the acceptability of ketamine and other glutamate receptor modulators in people with bipolar disorder who are experiencing acute depression symptoms...
2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26395901/ketamine-and-other-glutamate-receptor-modulators-for-depression-in-adults
#10
REVIEW
Caroline Caddy, Ben H Amit, Tayla L McCloud, Jennifer M Rendell, Toshi A Furukawa, Rupert McShane, Keith Hawton, Andrea Cipriani
BACKGROUND: Considering the ample evidence of involvement of the glutamate system in the pathophysiology of depression, pre-clinical and clinical studies have been conducted to assess the antidepressant efficacy of glutamate inhibition, and glutamate receptor modulators in particular. This review focuses on the use of glutamate receptor modulators in unipolar depression. OBJECTIVES: To assess the effects - and review the acceptability - of ketamine and other glutamate receptor modulators in comparison to placebo (or saline placebo), other pharmacologically active agents, or electroconvulsive therapy (ECT) in alleviating the acute symptoms of depression in people with unipolar major depressive disorder...
September 23, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26121895/effects-of-memantine-on-pain-in-patients-with-complex-regional-pain-syndrome-a-retrospective-study
#11
Mohammad-Hazem Ahmad-Sabry, Gholamreza Shareghi
INTRODUCTION: Memantine was discovered in 1968 and is used as a treatment for Alzheimer's disease. We evaluated the use of memantine to treat complex regional pain syndrome in this retrospective study. PATIENTS AND METHODS: 56 patients with CRPS, who were treated with trial of memantine for at least two months with 40mg QHS from 2007 until 2009. RESULTS: 34 females and 22 male patients. Age-46.0 +/- 9.7 years. Number of years with CRPS-9.24 ± 5...
February 2015: Middle East Journal of Anesthesiology
https://www.readbyqxmd.com/read/25519950/interventions-for-preventing-and-ameliorating-cognitive-deficits-in-adults-treated-with-cranial-irradiation
#12
REVIEW
Julia Day, Karolis Zienius, Karin Gehring, David Grosshans, Martin Taphoorn, Robin Grant, Jing Li, Paul D Brown
BACKGROUND: Cognitive deficits are common in people who have received cranial irradiation and have a serious impact on daily functioning and quality of life. The benefit of pharmacological and non-pharmacological treatment of cognitive deficits in this population is unclear. OBJECTIVES: To assess the effectiveness of interventions for preventing or ameliorating cognitive deficits in adult patients treated with cranial irradiation. SEARCH METHODS: In August 2014...
2014: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/25218600/efficacy-of-memantine-in-the-treatment-of-fibromyalgia-a-double-blind-randomised-controlled-trial-with-6-month-follow-up
#13
RANDOMIZED CONTROLLED TRIAL
Bárbara Olivan-Blázquez, Paola Herrera-Mercadal, Marta Puebla-Guedea, Mari-Cruz Pérez-Yus, Eva Andrés, Nicolas Fayed, Yolanda López-Del-Hoyo, Rosa Magallon, Miquel Roca, Javier Garcia-Campayo
Fibromyalgia (FM) is a prevalent and disabling chronic disease. Recent studies have found elevated levels of glutamate in several brain regions, leading to hypotheses about the usefulness of glutamate-blocking drugs such as memantine in the treatment of FM. The aim of this study was to evaluate the efficacy of memantine in the treatment of pain and other clinical variables (global function, clinical impression, depression, anxiety, quality of life) in FM patients. A double-blind, parallel randomised controlled trial was developed...
December 2014: Pain
https://www.readbyqxmd.com/read/24993765/treatment-effect-of-memantine-on-survival-in-dementia-with-lewy-bodies-and-parkinson-s-disease-with-dementia-a-prospective-study
#14
RANDOMIZED CONTROLLED TRIAL
Kajsa Stubendorff, Victoria Larsson, Clive Ballard, Lennart Minthon, Dag Aarsland, Elisabet Londos
OBJECTIVE: To investigate the effect on survival of treatment with memantine in patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). METHODS: 75 patients with DLB and PDD were included in a prospective double-blinded randomised placebo-controlled trial (RCT) of memantine, of whom long-term follow-up was available for 42. Treatment response was recorded 24 weeks from baseline and measured by Clinical Global Impression of Change (CGIC)...
2014: BMJ Open
https://www.readbyqxmd.com/read/24876182/pharmacological-treatment-of-neuropsychiatric-symptoms-in-alzheimer-s-disease-a-systematic-review-and-meta-analysis
#15
REVIEW
Jun Wang, Jin-Tai Yu, Hui-Fu Wang, Xiang-Fei Meng, Chong Wang, Chen-Chen Tan, Lan Tan
BACKGROUND: A wide variety of pharmacological agents are used in the management of neuropsychiatric symptoms, which are common in Alzheimer's disease (AD), but results from randomised controlled trials (RCTs) on the efficacy and safety of these agents are conflicting. OBJECTIVES: To quantify the efficacy and safety of pharmacological treatment on neuropsychiatric symptoms in AD patients. METHODS: Systematic review and meta-analysis of RCTs comparing pharmacological agents with placebo on Neuropsychiatric Inventory (NPI) and safety outcomes in AD patients with neuropsychiatric symptoms...
January 2015: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/24828899/efficacy-and-safety-of-cholinesterase-inhibitors-and-memantine-in-cognitive-impairment-in-parkinson-s-disease-parkinson-s-disease-dementia-and-dementia-with-lewy-bodies-systematic-review-with-meta-analysis-and-trial-sequential-analysis
#16
REVIEW
Hui-Fu Wang, Jin-Tai Yu, Shao-Wen Tang, Teng Jiang, Chen-Chen Tan, Xiang-Fei Meng, Chong Wang, Meng-Shan Tan, Lan Tan
OBJECTIVE: Recently, several large randomised controlled trials about the treatments of cognitive impairment or dementia due to Parkinson's disease (CIND-PD or PDD) and dementia with Lewy bodies (DLB) were completed. Here, we systematically reviewed the studies (including the recent reports) to provide updated evidence for the treatments of CIND-PD, PDD and DLB. METHODS: We searched Cochrane Dementia and Cognitive Improvement Group Specialised Register, Pubmed, Embase, and other sources for eligible trials...
February 2015: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/24737460/memantine-improves-attention-and-episodic-memory-in-parkinson-s-disease-dementia-and-dementia-with-lewy-bodies
#17
RANDOMIZED CONTROLLED TRIAL
Keith A Wesnes, Dag Aarsland, Clive Ballard, Elisabet Londos
OBJECTIVE: In both dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), attentional dysfunction is a core clinical feature together with disrupted episodic memory. This study evaluated the cognitive effects of memantine in DLB and PDD using automated tests of attention and episodic memory. METHODS: A randomised double-blind, placebo-controlled, 24-week three centre trial of memantine (20 mg/day) was conducted in which tests of attention (simple and choice reaction time) and word recognition (immediate and delayed) from the CDR System were administered prior to dosing and again at 12 and 24 weeks...
January 2015: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/24710130/the-effect-of-funding-sources-on-donepezil-randomised-controlled-trial-outcome-a-meta-analysis
#18
Lewis O J Killin, Tom C Russ, John M Starr, Sharon Abrahams, Sergio Della Sala
OBJECTIVE: To investigate whether there is a difference in the treatment effect of donepezil on cognition in Alzheimer disease between industry-funded and independent randomised controlled trials. DESIGN: Fixed effects meta-analysis of standardised effects of donepezil on cognition as measured by the Mini Mental State Examination and the Alzheimer's Disease Assessment Scale-cognitive subscale. DATA SOURCES: Studies included in the meta-analyses reported in the National Institute for Health and Care Excellence (NICE) technical appraisal 217 updated with new studies through a PubMed search...
April 7, 2014: BMJ Open
https://www.readbyqxmd.com/read/24626757/souvenaid%C3%A2-a-new-approach-to-management-of-early-alzheimer-s-disease
#19
C W Ritchie, J Bajwa, G Coleman, K Hope, R W Jones, M Lawton, M Marven, P Passmore
Synaptic loss correlates closely with cognitive deficits in Alzheimer's disease and represents a new target for intervention. Souvenaid® is the first medical nutrition product to be designed to support synapse formation and function in early Alzheimer's disease, and has undergone an extensive, 12-year development programme. The relatively large amount of clinical data available for Souvenaid® is unusual for a medical nutrition product. Souvenaid® contains omega-3 polyunsaturated fatty acids (docosahexaenoic acid and eicosapentaenoic acid), uridine (as uridine monophosphate) and choline which are nutritional precursors required for synaptic membrane phospholipid synthesis, together with phospholipids and other cofactors...
March 2014: Journal of Nutrition, Health & Aging
https://www.readbyqxmd.com/read/24510471/memantine-improves-goal-attainment-and-reduces-caregiver-burden-in-parkinson-s-disease-with-dementia
#20
RANDOMIZED CONTROLLED TRIAL
Iracema Leroi, Richard Atkinson, Ross Overshott
OBJECTIVE: Memantine, an uncompetitive antagonist of N-methyl-d-aspartate receptors, may have a role in managing symptoms associated with dementia in Parkinson's disease (PDD), although its role in improving patient-reported outcomes (PROs) has not been extensively investigated. PROs may be more sensitive than standard psychometric measures for detecting change in complex conditions such as PDD. The aim of this study was to examine the effect of memantine on PROs: individually determined goals and health-related quality of life...
September 2014: International Journal of Geriatric Psychiatry
keyword
keyword
81573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"